Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts.


Tumor angiogenesis plays a critical role in colorectal cancer progression. Recent randomized clinical trials have revealed the additive effect of bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF)-A, to conventional chemotherapy in the improved survival of patients with metastatic colorectal cancer. However, a… (More)
DOI: 10.1002/ijc.28686



Citations per Year

Citation Velocity: 10

Averaging 10 citations per year over the last 2 years.

Learn more about how we calculate this metric in our FAQ.